Literature DB >> 21692937

Correlation between promoter methylation of glutathione-S-tranferase P1 and oxidative stress in acute-on-chronic hepatitis B liver failure.

T Li1, Q H Meng, Z Q Zou, Y C Fan, B Long, Y M Guo, W Hou, J Zhao, J Li, H W Yu, Y K Zhu, K Wang.   

Abstract

Promoter methylation of glutathione-S-transferase P1 (GSTP1) may be involved in liver damage caused by oxidative stress in acute-on-chronic hepatitis B-induced liver failure (ACHBLF). This study aimed to explore GSTP1 promoter methylation status and oxidative stress in such patients. DNA was extracted from peripheral blood mononuclear cells (PBMCs) of patients with acute-on-chronic liver hepatitis B-induced liver failure, chronic hepatitis B (CHB) and normal controls, followed by sodium-bisulfite treatment and methylation-specific PCR (MSP) analysis. Plasma malondialdehyde (MDA) adducts levels were detected by enzyme-linked immunosorbent assay as oxidative stress marker. Model for end-stage liver disease (MELD) score was employed to estimate the severity of the liver failure. Eleven of 35 patients with acute-on-chronic liver failure and 3 of 35 patients with stab le hepatitis B displayed GSTP1 promoter methylation, and the difference was significant (χ2)  = 5.71, P = 0.02). No differences in standard liver function tests were found in patients with acute-on-chronic liver failure with and without GSTP1 promoter methylation although the levels of total bilirubin were greater in those with methylation. The levels of MDA adducts were significantly higher in patients with liver failure when compared to those with CHB (12.44 ± 5.38 pmol/mg vs 8.42 ± 5.49 pmol/mg, P < 0.01), and in the patients with liver failure who had promoter methylation the levels were higher than in those who did not (15.2 ± 4.68 pmol/mg vs 11.17 ± 5.29 pmol/mg, P < 0.01). The MELD score was not significantly different between methylated and unmethylated patients with liver failure (P > 0.05), although MDA adducts were correlated with MELD scores in patients with acute-on-chronic liver failure (r = 0.579, P < 0.01). GSTP1 promoter methylation may facilitate oxidative stress-associated liver damage in ACHBLF, and oxidative stress is correlated with ACHBLF severity.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692937     DOI: 10.1111/j.1365-2893.2011.01438.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  Prognostic value of plasma level of superoxide dismutase in HBV-related acute-on-chronic liver failure.

Authors:  Naijuan Yao; Yajuan He; Yuchao Wu; Fei Wang; Zhen Tian
Journal:  BMC Gastroenterol       Date:  2022-06-25       Impact factor: 2.847

2.  Aberrant GSTP1 promoter methylation predicts poor prognosis of acute-on-chronic hepatitis B pre-liver failure.

Authors:  Chen-Yang Qiao; Feng Li; Yue Teng; Jing Zhao; Na Hu; Yu-Chen Fan; Kai Wang
Journal:  Clin Exp Med       Date:  2017-07-04       Impact factor: 3.984

3.  Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study.

Authors:  Lei He; Li Gao; Zhe Shi; Yuhong Li; Lingyan Zhu; Shiming Li; Peng Zhang; Guoying Zheng; Qi Ren; Yun Li; Bo Hu; Fumin Feng
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Association of glutathione S-transferases (GSTT1, GSTM1 and GSTP1) genes polymorphisms with nonalcoholic fatty liver disease susceptibility: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Yi Zhu; Jian-Hua Yang; Jun-Ping Hu; Ming Qiao
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

Review 5.  Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis.

Authors:  Alexander V Ivanov; Vladimir T Valuev-Elliston; Daria A Tyurina; Olga N Ivanova; Sergey N Kochetkov; Birke Bartosch; Maria G Isaguliants
Journal:  Oncotarget       Date:  2017-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.